Age disparities in lung cancer survival in New Zealand: The role of patient and clinical factors.


Journal

Lung cancer (Amsterdam, Netherlands)
ISSN: 1872-8332
Titre abrégé: Lung Cancer
Pays: Ireland
ID NLM: 8800805

Informations de publication

Date de publication:
07 2021
Historique:
received: 21 02 2021
revised: 05 05 2021
accepted: 10 05 2021
pubmed: 20 5 2021
medline: 25 6 2021
entrez: 19 5 2021
Statut: ppublish

Résumé

Age is an important prognostic factor for lung cancer. However, no studies have investigated the age difference in lung cancer survival per se. We, therefore, described the role of patient-related and clinical factors on the age pattern in lung cancer excess mortality hazard by stage at diagnosis in New Zealand. We extracted 22 487 new lung cancer cases aged 50-99 (median age = 71, 47.1 % females) diagnosed between 1 January 2006 and 31 July 2017 from the New Zealand population-based cancer registry and followed up to December 2019. We modelled the effect of age at diagnosis, sex, ethnicity, deprivation, comorbidity, and emergency presentation on the excess mortality hazard by stage at diagnosis, and we derived corresponding lung cancer net survival. The age difference in net survival was particularly marked for localised and regional lung cancers, with a sharp decline in survival from the age of 70. No identified factors influenced age disparities in patients with localised cancer. However, for other stages, females had a greater difference in survival between middle-age and older-age than males. Comorbidity and emergency presentation played a minor role. Ethnicity and deprivation did not influence age disparities in lung cancer survival. Sex and stage at diagnosis were the most important factors of age disparities in lung cancer survival in New Zealand.

Identifiants

pubmed: 34006378
pii: S0169-5002(21)00194-X
doi: 10.1016/j.lungcan.2021.05.015
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

92-99

Informations de copyright

Copyright © 2021 The Author(s). Published by Elsevier B.V. All rights reserved.

Auteurs

Sophie Pilleron (S)

Department of Public Health, University of Otago, PO Box 7343, Wellington, New Zealand; Nuffield Department of Population Health, University of Oxford, Big Data Institute, Old Road Campus, Oxford, OX3 7LF, UK. Electronic address: sophie.pilleron@ndph.ox.ac.uk.

Camille Maringe (C)

Inequalities in Cancer Outcomes Network, London School of Hygiene and Tropical Medicine, Keppel Street, London, WC1E 7HT, UK. Electronic address: Camille.Maringe@LSHTM.ac.uk.

Hadrien Charvat (H)

Epidemiology and Prevention Group, Center for Public Health Sciences, National Cancer Center, Tokyo, Japan; Section of Cancer Surveillance, International Agency for Research on Cancer, Lyon, France. Electronic address: chadrien@ncc.go.jp.

June Atkinson (J)

Department of Public Health, University of Otago, PO Box 7343, Wellington, New Zealand. Electronic address: june.atkinson@otago.ac.nz.

Eva Morris (E)

Nuffield Department of Population Health, University of Oxford, Big Data Institute, Old Road Campus, Oxford, OX3 7LF, UK. Electronic address: https://www.twitter.com/EJAMorris.

Diana Sarfati (D)

Department of Public Health, University of Otago, PO Box 7343, Wellington, New Zealand. Electronic address: https://www.twitter.com/DiSarfati.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH